AUSTIN, Texas, Dec. 18 Rules-Based Medicine, Inc. (RBM)and Correlogic Systems, Inc. today announced the award of a National CancerInstitute (NCI) Small Business Innovation Research (SBIR) contract to RBM thatwill further research on ovarian cancer diagnostic tests. The contract wasawarded through a peer-reviewed competitive process to develop biomarkerpanels for the early detection of cancer and includes a Phase I "Fast-Track"component and Phase II option, together totaling $1.15 million.
RBM, located in Austin, Texas, is the world's leading multiplexedbiomarker testing laboratory delivering robust assay data with applications indrug safety and efficacy, disease diagnosis and disease modeling. Correlogic,based in Rockville, MD, has pioneered the use of pattern recognitiontechnologies for the development of proteomic, metabolomic, and genomic-basedclinical prognostic and clinical diagnostic tests. The companies havecollaborated on production of Correlogic's first ovarian cancer diagnostictest, OvaCheck(R).
"An early diagnostic screen for ovarian cancer could greatly increase thechances of survival," said Craig Benson, RBM's chief executive officer. "Ourresearch will integrate additional biomarkers associated with ovarian cancerinto the existing Correlogic panel with the aim of achieving sensitivity andspecificity levels that can open this test to a wider population of women."
"Our search for additional biomarkers -- and combinations ofbiomarkers -- for early disease detection is an ongoing effort," said PeterLevine, Correlogic's president and chief executive officer. "We are buildingon Correlogic's extensive research and validation using multiple markers fordisease detection to take our test to the next level."
Under the two phases of this project, RBM will develop and testquantitative, multiplexed immunoassays incorporating 19 additional analytesthe two companies have identified as promising targets potentially capable ofenhancing accuracy of ovarian cancer detection. Correlogic will expand itsexisting analytic platform to determine the efficacy of incorporating theseadditional analytes into the existing assay. Upon completion RBM will add the19 assays to its automated RBM Human Multi-Analyte Profile platform,HumanMAP(R).
The project is being funded in whole or in part with Federal funds fromthe NCI, the National Institutes of Health, and the Department of Health andHuman Services under Contract No. HHSN261200800045C. RBM received two"fast-track" SBIR awards in 2007.
About Ovarian Cancer
The American Cancer Society estimates ovarian cancer will strike 21,650women and take the lives of 15,520 women in 2008. It is the most deadlygynecologic cancer, accounting for more than 55 percent of all gynecologiccancer deaths. But ovarian cancer is also among the most treatable if it iscaught early. When ovarian cancer is diagnosed early and appropriatelytreated, 5-year survival is 93 percent. However, less than 20 percent of allovarian cancers are found in this early stage. Progress continues, with thedevelopment of new tests to aid in diagnosis of certain symptomatic women.With further enhanced sensitivity and specificity that additional research mayprovide, tests can be appropriate for a wider population of women.
About Rules-Based Medicine
Rules-Based Medicine (RBM) provides comprehensive protein biomarkerproducts and services centered on its Multi-Analyte Profiling (MAP)technology. Its service platform (RodentMAP(R) and HumanMAP(R)) providespre-clinical and clinical researchers with reproducible, quantitative,multiplexed immunoassay data for hundreds of proteins cost-effectively inmultiple species, and from a small sample volume. The Company also offersinnovative and proprietary ex vivo testing systems such as TruCulture(TM), thefirst fully-closed, reproducible whole blood culture system. RBM is activelydeveloping multiplex diagnostic tests to detect the presence of complexdiseases and conditions in areas of unmet medical need such asneuropsychiatry, nephrology, immunology and cardiology. More information aboutRBM is located at http://www.rbmmaps.com.
About Correlogic Systems
Correlogic Systems, Inc. has developed patented technology and processeswith a wide variety of applications for biomarker discovery, diseasedetection, and new drug discovery. The technology's first application has beenin the field of proteomics - the study of human proteins. OvaCheck(R), a bloodtest for detection of ovarian cancer, is Correlogic's first diagnostic testusing its patented "Hidden Patterns" approach. Correlogic has entered intomarketing agreements with Quest Diagnostics, Inc., and Laboratory Corporationof America for OvaCheck in North America. Correlogic's pipeline includes bloodtests for colon, breast and prostate cancer. Quest Diagnostics, Mitsui & Co.,Ltd., and Ahn-Gook Pharmaceutical Co., Ltd. are equity investors inCorrelogic. Visit Correlogic at http://www.correlogic.com.
Cautionary Statement: Certain statements contained in this release areforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements are based on management'scurrent expectations and are subject to uncertainty and changes incircumstances. Actual results could differ materially due to, among otherthings, operational and other difficulties associated with integratingacquired business, general business conditions, competition among managed carecompanies, rising health costs, trends in medical loss ratios, health carereform, delay in receipt of regulatory and other approvals for pendingtransactions and other regulatory issues.
RodentMAP(R) and HumanMAP(R) are registered trademarks of Rules-BasedMedicine, Inc. OvaCheck(R) is a registered trademark of Correlogic Systems,Inc.
SOURCE Rules-Based Medicine, Inc.